Oncology Pharma Inc.

Empowering  

Physicians and Cancer Patients

Mission Statement
To further the development of cancer treatments for improving quality of life of patients and to extend longevity
Oncology Pharma Inc. - About

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics.  The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.

Oncology Pharma entered into a Licensing Agreement with NanoSmart®Pharmaceuticals Inc. for its "novel" drug delivery platform that can target many types of cancer and other diseases. One of the keys to NanoSmart's® platform technology is a “patented”(US 7,799,327 and EU 1706145 B1) human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors.  One of the most commonly used anti-cancer drugs, alone and/or in combination with medications, for treating a wide variety of cancers such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin.

 

Doxorubicin is “encapsulated” within a lipid nanoparticle and then coated with NanoSmart’s ANA.  The "reformulated" drug, doxorubicin, is administered intravenously, traveling in the blood to the tumor site(s).  Encapsulating the cancer drug in the nanoparticle helps protect normal, healthy tissues and organs from adverse side effects, while the ANA delivers the loaded nanoparticle directly to necrotic tissue at the tumor site(s).  Once anchored there, the nanoparticle slowly releases the cancer drug with an optimal efficacy and minimum adverse effects. The results are thus higher anti-tumor efficacy and safer drug delivery.

 

Therapeutic dosing can be optimized, and adverse side effects can be further minimized using pharmacogenetics combined with artificial intelligence and machine learning.  

Oncology Pharma signed a Licensing Agreement with Connect2Med for its smartphone App.  The use of mobile devices such as Smartphones and their applications (Apps) has transformed many aspects of life in the modern world from consumer healthcare to clinical practice and limited use in clinical trials. The App is a powerful and useful tool for recruiting, enrolling and supporting patients for clinical trials.

Oncology Pharma has licensed from KCL Therapeutics, Inc. Small molecule modulators of NR2F6 Activity for treatment in humans of colon cancer.  The IP entails compounds useful for alteration of NR2F6 activity. In some embodiments of the invention compounds disclosed are utilized for stimulation of NR2F6 activity, alone, or in combination with PKC activation. In other embodiments , the invention teaches use of compounds for inhibition of NR2F6 activation . Stimulation of NR2F6 within the context of the invention is useful, intra alia , for induction of immune inhibition , or stimulation of cellular proliferation without significant induction of differentiation . Inhibition of NR2F6 is desired in situations where the practitioner of the invention seeks to augment immune response, or induce cellular differentiation. In another embodiment, inhibition of NR2F6  expression is desired in situations where inhibition of cancer or cancer stem cells is needed.

In a further Licensing Agreement, Oncology Pharma has licensed from Regen Biopharma, Inc. an Antigen Specific mRNA Cellular Cancer Vaccine IP for treatment in human pancreatic cancer.     The IP entails antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes.  In one embodiment of the IP, said modified mRNA encodes peptides derived from the protein surviving.  By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.

With these established Agreements, Oncology Pharma is poised to help transform the current landscape of oncology treatment to seeking a faster regulatory process, improve the delivery system of cancer fighting drugs, develop an anti-cancer method with decreased toxicity, while improving technology to be utilized by doctors, researchers and patients.  This diversified strategy is what the world class team of advisors and directors are focusing on developing to help in the fight against cancer and other opportunities within the expertise of our Board and Advisors..